Medicare Panel Backs Prostate Drug
17 November 2010
By Andrew Pollack, New York Times
A federal advisory committee said Wednesday that there was
adequate evidence that the drug Provenge prolongs the lives of men
with advanced prostate cancer, an endorsement that makes it more
likely that Medicare will pay for the $93,000 treatment.
The Medicare Coverage Advisory Committee voted that it had
"intermediate confidence'' in the strength of the data that the
drug, developed by Dendreon, improves survival.
The meeting Wednesday is part of a process in which the Centers
for Medicare and Medicaid Services is deciding whether to pay for
Provenge, which was approved by the Food and Drug Administration in
April.
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
